Technical Analysis for CRY - CryoLife, Inc.

CRY closed up 2.33 percent on Wednesday, November 25, 2015, on 43 percent of normal volume.

Rating Last Price % Change $ Change
grade A $11.00 2.33% 0.25
Track This Stock
Watchlist Portfolio
ADX Long-Term Mid-Term Short-Term
Weak or Absent Up Up Up
See historical CRY trend table...

Date Name Bull/Bear
2015-11-24 Upside 200 DMA Break Bullish
2015-11-24 Bullish Engulfing Bullish
2015-11-24 Stochastic Buy Signal Bullish
2015-11-24 180 Bullish Setup Bullish Swing Setup
2015-11-23 Doji - Bullish? Reversal
2015-11-20 200 DMA Resistance Bearish
2015-11-20 Bearish Engulfing Bearish
2015-11-19 200 DMA Resistance Bearish
2015-11-19 Doji - Bullish? Reversal
2015-11-18 200 DMA Resistance Bearish

See older technical analysis pattern alerts for CRY ...
Buy or Sell?
Is CRY a Buy, Sell or Hold?:
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Sector: Health Care

Industry: Medical/Dental Instruments

CryoLife, Inc. preserves and distributes human tissues for transplantation in the United States and internationally. The company also develops, manufactures, and commercializes medical devices for cardiac and vascular applications. It distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using CryoLifeÂ’s proprietary SynerGraft technology; and vascular tissues comprising CryoVein and CryoArtery to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company also distributes surgical sealants and hemostats, including BioGlue Surgical Adhesive, an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels, as well as in repair of cardiac, vascular, pulmonary, and additional soft tissues. In addition, its surgical sealants and hemostats comprise BioFoam Surgical Matrix for use as an adjunct in the sealing of abdominal parenchymal tissues, when cessation of bleeding by ligature or conventional methods is ineffective or impractical; PerClot, an absorbable powdered hemostat agent used in surgery; and revascularization technologies, which include transmyocardial revascularization system for treating patients with stable angina that is not responsive to conventional therapy. CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization. The company, through its subsidiary, Hemosphere, Inc., markets HeRO Graft, a solution for end-stage renal disease in certain hemodialysis patients. CryoLife distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Recent Messages:
Earnings date: 2015-10-27

Indicator Value
52 Week High 12.18
52 Week Low 9.38
Average Volume 64,499
200-Day Moving Average 10.46
50-Day Moving Average 10.25
20-Day Moving Average 10.61
10-Day Moving Average 10.5
Average True Range 0.27
ADX 20.85
+DI 28.61
-DI: 13.39
Chandelier Exit (Long, 3 ATRs) 10.19
Chandelier Exit (Short, 3 ATRs) 10.45
Upper Bollinger Band 11.01
Lower Bollinger Band 10.21
Percent B (%b) 0.99
Bandwidth 0.075401

You must be logged in to access portfolios.

Sign up